OncoCyte Corporation with ticker code (OCX) now have 7 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 11 and 2 with a mean TP of 7.71. With the stocks previous close at 4.75 this is indicating there is a potential upside of 62.3%. The day 50 moving average is 5.2 and the 200 day MA is 2.97. The company has a market capitalisation of $433m. You can visit the company’s website by visiting: http://oncocyte.com
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation was founded in 2009 and is headquartered in Irvine, California.